Pharmaceutical Editorial
  • Home
  • News
  • About
  • Contact

I am Elekta

Cancer, Elekta, Medical, Pharmaceuticals, Press Releases, Surgical

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Elekta is the world leader in image guided and stereotactic clinical solutions for radiosurgery and radiation therapy, giving radiation oncologists and neurosurgeons an unmatched capability to aggressively treat tumors and functional targets with ultra-high precision while sparing healthy tissue.

Elekta develops its clinical solutions and information systems through close collaborative relationships with customer partners in research and advanced product development. Through these efforts Elekta is addressing the needs of healthcare systems as well as patients by reducing hospitalization costs and providing less traumatic treatment options.

Elekta was founded in 1972 by the late Lars Leksell, Professor of Neurosurgery at the Karolinska Institute in Stockholm, Sweden. Today, Elekta solutions in oncology and neurosurgery are used in 6,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 3,300 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.

SOURCE: Elekta

Related Posts

Medical, Pharmaceutical, Pharmaceuticals, Press Releases

Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting

Allergan, Medical, Pharmaceutical, Pharmaceuticals, Press Releases

Allergan’s Eyepowerment™ Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications

Medical, Pharmaceutical, Pharmaceuticals, Press Releases

The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures

Featured News

  • Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting
  • Allergan’s Eyepowerment™ Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications
  • The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures
  • Abbott Announces CE Mark for Tacticath™ Contact Force Ablation Catheter, Sensor Enabled™
  • Abbott Announces CE Mark and First Use of the World’s First SmartPhone Compatible Insertable Cardiac Monitor
Pharmaceutical Editorial
Copyright © PhysicianEditorial.com
All Rights Reserved!